<Record>
<Term>Yttrium 90-DOTA-Chimeric Monoclonal Antibody cG250</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Radioimmunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Radiopharmaceutical Compound/Radioimmunoconjugate/Yttrium 90-DOTA-Chimeric Monoclonal Antibody cG250</ClassificationPath>
<BroaderTerm>Radioimmunoconjugate</BroaderTerm>
<BroaderTerm>Radiopharmaceutical Compound</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Yttrium 90-DOTA-Chimeric Monoclonal Antibody cG250</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>90Y-DOTA-cG250</Synonym>
<Synonym>Yttrium 90-DOTA-Chimeric Monoclonal Antibody cG250</Synonym>
<Synonym>Yttrium-90 DOTA Conjugated Chimeric MoAb G250</Synonym>
<Description>A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting radioisotope yttrium 90. The antibody moiety of yttrium 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.</Description>
<Source>NCI Thesaurus</Source>
</Record>
